Denis Jusufbegovic, M.D.
Sub-Specialty: Macula-Retina-Vitreous Services
Practice: Raj K. Maturi, M.D., P.C.
PracticeID: MEIRKM 317-817-1414
Services, Procedures and Patient-Care Specialties
Surgeries and Procedures:
Vitrectomy for macular disorders, complex retinal detachment repair, scleral buckle and pneumatic retinopexy, submacular and vitreous procedures, retinal laser photocoagulation, and cryotherapy
Intravitreal pharmacologic therapies, including anti-VEGF and corticosteroid injections, and laser-based treatments for diabetic and vascular retinal diseases
Diagnostic:
Optical Coherence Tomography (OCT and OCT-A), Widefield Fluorescein and Indocyanine Green Angiography (OPTOS UWF), Fundus Autofluorescence, Digital Fundus Photography, B-scan Ultrasonography, and Multifocal and Full-Field Electroretinography (ERG)
Education
Medical School- University of Louisville, Louisville, KY, M.D. 2005-2009
University- Bellarmine University, Louisville, KY, B.S.H. in Cytotechnology 2001-2003
Honors/Awards
Indiana University Trustee Teaching Award (2022)
Professor of the Year, IU Dept. of Ophthalmology (2019)
Vit-Buckle Society Annual Meeting VBS 004 Travel Award (2016)
Louisville Residents' Day Best Research Presentation Award (2013)
Excellence in Clinical Education Award (2012)
Alpha Omega Alpha Medical Honor Society (2009)
Pathology Honor Society (2007)
Clinical Associate Award for Best Performing Student (2003)
Dean's List (2001-2003)
Internship
University of Louisville, Louisville, KY, Internal Medicine 2009-2010
Residency
University of Louisville, Louisville, KY, Ophthalmology 2010-2013
Fellowship
University of Louisville, Louisville, KY, Vitreoretinal Surgery 2014-2016
Tumori Foundation/CPMC, San Francisco, CA, Ocular Oncology 2013-2014
Professional Development
Business of Medicine Emerging Leadership Program (Fall 2019)
Memberships
American Society of Retina Specialists (2014-) American Academy of Ophthalmology (2010-)
Kentucky Academy of Eye Physicians and Surgeons (2010-2016) Kentucky Medical Association (2009-2016)
Greater Louisville Medical Society (2009-2016)
Academic Appointments
Associate Professor, Department of Ophthalmology, Indiana University, Indianapolis, IN (2016-2025)
Board/Other Certifications
American Board of Ophthalmology (2014-)
Research
Publications
Patel SH, Badar A, Bakhsh S, Jusufbegovic D. Bilateral Cystoid Macular Edema Following Bimatoprost Implants. Retin Cases Brief Rep. 2024 Mar1;18(2):218-220
Shughoury A, Bhatwadekar A, Jusufbegovic D, Hajrasouliha A, Ciulla TA. The evolving therapeutic landscape of diabetic retinopathy. Expert Opin Biol Ther. 2023 Jul-Dec;23(10):969-985.
Camp DA, Price DA, Neiweem AE, Jusufbegovic D. Effects of intravitreal bevacizumab therapy on glomerular filtration rate in patients treated for proliferative diabetic retinopathy. Retina. 2022 Aug 17.
Patel S, Belamkar A, Hajrasouliha AR, Jusufbegovic D, Ciulla TA. Progress in the pharmacotherapy of uveitis: the art of personalized care. Expert Opin Pharmacother. 2022 Aug;23(12):1445-1455
Jacobs B, Palmer N, Shetty T, Dimaras H, Hajrasouliha A, Jusufbegovic D, Corson T. Patient preferences in retinal drug delivery. Scientific Reports. Sci Rep. 2021 Sep 23;11(1):18996.
Neiweem AE, Jusufbegovic D. Branch Retinal Artery Occlusion Associated with Toxoplasma Retinitis. Korean J Ophthalmol. 2020 Aug;34(4):341-342.
Book Chapter
Kalafatis NE, Bakhsh S, Jusufbegovic D. Choroid Hemangioma Circumscribed. In Clinical Cases in Ocular Oncology 2025 Jan 1 (pp. 264-267)
Rowe LW, Jusufbegovic D, Singh AD. Ocular Complications of Targeted Therapy. In Clinical Ophthalmic Oncology: Retinal Tumors 2024 Dec 31 (pp. 151-164). Cham: Springer Nature Switzerland.
Lambert-Cheatham N., Jusufbegovic D., Corson TW. Intraocular and Orbital Cancers. In Comprehensive Pharmacology 2020.
Aebi B, Jusufbegovic D. Management of Choroidal Hemangioma. In Ocular Oncology 2019 (pp. 95-114) Springer Nature.
Neiweem A, Jusufbegovic D, Singh AD. Ocular Complications of Targeted Therapy. In Clinical Ophthalmic Oncology 2019 (pp. 143-159). Springer, Cham.
Jusufbegovic D, Triozzi PL, Singh AD. (2014). Targeted Therapy and Their Ocular Complications. In Clinical Ophthalmic Oncology (pp. 123-132). Springer Berlin Heidelberg
Abstracts and Presentations
Pellerano F, Hepp C, Cabrero G, Ramchandani M, Yun E, Jusufbegovic D. Adverse Events After Resident-Performed Intravitreal Injection. AAO 2025
Jusufbegovic D, Rowe L, Camp D, Levergood N. Real-world Visual Acuity Outcomes Following Treatment for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy in a Socioeconomically Disadvantaged Population. ASRS 2024
Sevgi DD, Dong K, Miller V, Jusufbegovic D. Infiltrative Optic Neuropathy in Acute Lymphoblastic Leukemia with Negative Bone Marrow Biopsy. YMDC Live 2023
Cory MT, Patel JS, Jusufbegovic D, Bhatwadekar A. Circadian Rhythm Types in Individuals with Diabetic Macular Edema. Proceedings of IMPRS. 2022;5(1).
Ross E, Jusufbegovic D. Choroidal Melanoma Masquerading as Neovascular Glaucoma. Woman in Ophthalmology Summer Symposium 2021
Palmer N, Jacobs B, Shetty T, Dimaras H, Hajrasouliha A, Jusufbegovic D, Corson TW. Patient preferences in retinal drug delivery. ARVO 2021
Price D, Neiweem A, Jusufbegovic D. Effects of intravitreal anti-vascular endothelial growth factor therapy on kidney function in patients treated for proliferative diabetic retinopathy. ARVO 2020
Rameswara V, Blevins A, Eckert G, Jusufbegovic D, Bhatwadekar A. Effects of Irregular Shifts on Incidence of Type II Diabetes Among Healthcare Workers.
Proceedings of IMPRS. December 2020
Singh C, Jusufbegovic D, Lind J, Pattabirman P. Glaucoma and Diabetes: A Sweet Connection. Proceedings of IMPRS. December 2020
Clinical Trials/Research
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD, Protocol AO
Genes in Diabetic Retinopathy Project
Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS), Novo Nordisk A/S (2019-present)
Sub-Investigator, Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients, Ionis Pharmaceuticals, Inc. (2019-2021)